Titles
- Best practices for convening a GRAS panel: guidance for industry1
- Billions in estimated Medicare Advantage payments from diagnoses reported only on health risk assessments raise concerns1
- Biomedical research: information on federal contributions to remdesivir : report to Congressional addressees1
- Black Lung Benefits Program: oversight is needed to address trust fund solvency strained by bankruptcies : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Black Lung benefits program: continued inaction on coal operator self-insurance increases financial risk to trust fund : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Breakthrough Devices Program: guidance for industry and Food and Drug Administration staff1
- Bridging the gaps: state and local strategies for ensuring backup personal care services1
- Bureau of Prisons: assessment of health care reentry policies and procedures needed : report to congressional committees1
- CARES Act: experts identified safeguards to help selected HHS agencies protect against potential political interference : report to congressional requesters1
- CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight1
- CDC has improved the nursing home reporting process for COVID-19 Data in NHSN, but challenges remain1
- CDC provided oversight and assistance: however, ELC recipients still faced challenges in implementing COVID-19 screening testing programs1
- CDC’S Vaccines for Children program recipients did not conduct site visits at some providers as required1
- CDC’s internal control weaknesses led to its initial COVID-19 test kit failure, but CDC ultimately created a working test kit1
- CDER’s program for the recognition of voluntary consensus standards related to pharmaceutical quality: guidance for industry1
- CMS can do more to leverage Medicare claims data to identify unreported incidents of potential abuse or neglect1
- CMS could improve the data it uses to monitor antipsychotic drugs in nursing homes1
- CMS has opportunities to strengthen states’ oversight of Medicaid Managed Care Plans’ reporting of medical loss ratios1
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- CMS should pursue strategies to increase the number of at-risk beneficiaries acquiring naloxone through Medicaid1